Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
LOS ANGELES, March 08, 2018 -- ViaDerma, Inc. (OTC Pink:VDRM), is pleased to provide an update of the Company’s current marketing activities:
- ViaDerma is in discussions with a Huntington Beach based international consulting firm, to explore placement of Vitastem in Infomercials, a nationwide pharmacy chain with 9600 stores domestically, and foreign placements throughout the Middle-East and Dubai.
- Discussions are also ongoing with representatives from a nationwide pharmaceutical distributor regarding distribution of Vitastem through their affiliated pharmacies and hospitals throughout the US, as well as distribution in the veterinary market though their association with veterinary suppliers nationwide.
- ViaDerma is awaiting a formal proposal from CMD Innovations, LLC, to use Vitastem in their wound healing protocol. CMD provides effective medical solutions for healthcare facilities including V.A. Hospitals.
- Negotiations are ongoing with a large, regional medical supply sales force for product distribution in pharmacies throughout the Southern United States.
- Vitastem is currently undergoing an approval process by government regulatory agencies in Nigeria and the Philippines. Upon approval, Vitastem will be distributed to hospitals in those countries and the Philippines prison system.
- Begun the process for approval of Vitastem by Medicare and other insurance companies reimbursement.
- ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
- Last month ViaDerma was a proud sponsor at “SB52 Big Game Event” held during Superbowl weekend in Minneapolis, organized by The Brewer Group, a marketing, media and consulting firm founded by former NFL player, Jack Brewer.
Dr. Christopher Otiko, President of ViaDerma, stated, “We are very excited in the direction we are headed with our product distribution efforts. We will provide further updates to these and other initiatives as developments unfold.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: [email protected]
Phone: 310-374-6111
